HANOVER, Mass., March 2 /PRNewswire/ -- Xennex, Inc. (Xennex) announced today the release of GeneCards(R), Version 3.0, available at http://www.genecards.org.
Dr. David Warshawsky, Chairman of Xennex, stated: "We are delighted to see the deployment of GeneCards Version 3.0. It will enable users around the world to better perform cutting-edge research in various fields of biology and medicine, and in the discovery and development of diagnostics and therapeutics."
GeneCards(R) (http://www.genecards.org) is a searchable, integrated database of human genes that provides concise genomic, transcriptomic, genetic, proteomic, functional and disease-related information on all known and predicted human genes. Information is featured in 18 GeneCards sections and includes orthologies, disease relationships, mutations and SNPs, gene expression, gene function, pathways, protein-protein interactions, related drugs and compounds and direct links to valuable research reagents and tools such as antibodies, recombinant proteins, clones, expression assays and RNAi reagents. GeneCards was developed over the last 13 years by a world-leading bioinformatics team at the Weizmann Institute of Science in Israel, directed by Marilyn Safran and by Professor Doron Lancet of the Department of Molecular Genetics, Head of the Crown Human Genome Center, and the incumbent of the Ralph & Lois Silver Professorial Chair of Human Genomics at the Weizmann Institute of Science.
Founded in 2003, Xennex, Inc. (http://www.xennexinc.com) is a dynamic privately held company that is dedicated to providing Biotechnology, Pharmaceutical and other life sciences companies, as well as organizations dealing with biotechnology intellectual property, the highest level of services and tools to enhance their gene-based research. Xennex' products help such organizations to optimize their efforts to develop innovative medical products and services.
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.